National Institute of Allergy and Infectious Diseases (NIAID): HIV Infections trials

The registry lists 728 HIV Infections studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 9 are open to participants now and 104 have results posted.

Phase 1 327Phase 2 183Phase 3 57Phase 4 7No phase 195(a study in two phases counts in both)

Studies

Page 4 of 8. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Immunologic Control of Drug Resistant HIVStatus unknownNCT00053404
• Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected PatientsCompletedNCT00052182Phase 1
• Development of a New HIV VaccineCompletedNCT00051922Phase 1
• Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive AdultsCompletedNCT00051831Not applicable
• Promoting Adherence to Anti-HIV Drug RegimensCompletedNCT00051805Not applicable
• Computer-Assisted Adherence Program for Patients Taking Anti-HIV DrugsTerminatedNCT00051766Not applicable
• Screening HIV-Infected Patients for Vaccine StudiesCompletedNCT00051519
• Evaluation of the Safety of and Immune Response to an HIV Vaccine in Healthy AdultsCompletedNCT00051454Phase 1/2
• Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIVWithdrawnNCT00051090Not applicable
• Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)WithdrawnNCT00051077Phase 2
• Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV DrugsCompletedNCT00050921Not applicable
• Blood Vessel Function in HIV-Infected Patients Taking Anti-HIV DrugsCompletedNCT00050908
• Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2CompletedNCT00050726Phase 2
• Discontinuation of Antiretroviral Therapy in Patients With Asymptomatic HIV InfectionCompletedNCT00050284
• Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV DrugsCompletedNCT00050063
• HIV Prevention Preparedness StudyCompletedNCT00048282
• Rapid HIV Tests for Women Late in Pregnancy and During LaborTerminatedNCT00046436
• Multicenter AIDS Cohort Study (MACS)Status unknownNCT00046280
• Comparing Standard-Dose Versus Adjusted-Dose Lopinavir/Ritonavir Therapy in HIV-Infected Persons With Drug ResistanceCompletedNCT00046033Phase 2
• Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal WomenTerminatedNCT00044837Phase 1
• HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)CompletedNCT00043641
• Safety of an HIV DNA Vaccine Given to HIV Uninfected AdultsCompletedNCT00043511Phase 1
• A Study of HIV Levels During Pregnancy and After ChildbirthCompletedNCT00041964
• Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease InhibitorCompletedNCT00041769Phase 3
• A Study of Peer Education to Prevent HIV Transmission Among Injection Drug Users and Their HIV Risk ContactsCompletedNCT00038688Phase 3
• Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected InfantsCompletedNCT00038480Phase 1
• A Study of DAPD Alone Versus DAPD Plus MMF for Treatment of HIV InfectionCompletedNCT00038272Phase 2
• Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug TherapyCompletedNCT00038259Not applicable
• A Study to See if Certain Antioxidants and Vitamins Will Keep Lactate Levels Down in Patients Taking Anti-HIV DrugsWithdrawnNCT00037063Not applicable
• Effects of Changing HIV Therapy at Lower Versus Higher Viral LoadsCompletedNCT00036465Phase 2
• A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct ObservationCompletedNCT00036452Phase 2
• Study of Anti-HIV Therapy IntensificationCompletedNCT00034086Not applicable
• Screening Protocol for HIV Vaccine StudiesCompletedNCT00031304
• The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in MonkeysCompletedNCT00031109Not applicable
• Increasing HAART-Induced Immune Restoration With CyclosporineCompletedNCT00031070Phase 2
• Adding New Drugs for HIV Infected Patients Failing Current TherapyCompletedNCT00031044Phase 1/2
• A Study to Prepare for Future HIV Vaccine StudiesCompletedNCT00029744
• A Study to Demonstrate That Anti-HIV Drug Therapy Can be Stopped Without Causing Viral Resistance, and to Characterize Drug Elimination From the BodyCompletedNCT00029341Phase 2
• Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected PeopleCompletedNCT00028366Not applicable
• Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive CareCompletedNCT00028327Phase 3
• Safety and Acceptability of the Anti-Microbe Vaginal Gel, PMPA GelCompletedNCT00028132Phase 1
• Immune Responses to HIV in Blood Cells in HIV-Infected and HIV-Uninfected VolunteersCompletedNCT00027482
• An Investigational Combination Vaccine Given to People Who Are Not Infected With HIVCompletedNCT00027365Phase 1
• A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)CompletedNCT00027352
• Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIVCompletedNCT00027339Phase 2
• Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected AdultsCompletedNCT00027261Phase 1
• Use of a Test That Evaluates How the Body Handles Insulin and GlucoseCompletedNCT00027092
• Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SCCompletedNCT00026624Phase 1
• Influenza Vaccine in HIV Infection: Immune Response and Effect on Viral LoadCompletedNCT00025922
• Intermittent vs. Continuous HAART to Treat Chronic HIV InfectionCompletedNCT00025909Phase 3
• Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV InfectionCompletedNCT00023153Phase 3
• HIV Prevention Preparedness Study in Russia, China, and IndiaCompletedNCT00021775
• Effects of Immunization With HIV-1 Immunogen Plus Anti-HIV Treatment Interruption on the Levels of HIVWithdrawnNCT00021762Phase 2
• Mycophenolate Mofetil and Abacavir Treatment in HIV Patients With Failed Anti-HIV TreatmentWithdrawnNCT00021489Phase 2
• Problems Associated With the Use of Anti-HIV Drugs in HIV-Infected Pregnant WomenCompletedNCT00017797
• Nerve Damage in Patients With HIV Infection Who Have Been Treated With Anti-HIV DrugsCompletedNCT00017771
• Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During PregnancyCompletedNCT00017719Phase 3
• Stopping and Restarting Anti-HIV Drugs in Children and Adolescents With Low Blood Levels of HIVCompletedNCT00016783
• Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected WomenCompletedNCT00016601Not applicable
• Effects of BufferGel and PRO 2000/5 Gel in MenCompletedNCT00016536Phase 1
• Effect of Interleukin-2 on HIV Treatment InterruptionCompletedNCT00015704Not applicable
• Interleukin-2 (IL-2), Pegylated Interferon (PEG-IFN Alfa-2b), and Ribavirin (RBV) Treatment in Patients With Hepatitis C and HIV CoinfectionCompletedNCT00015652Not applicable
• Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination RegimenCompletedNCT00014937Not applicable
• A Study of Immune System Activity in Healthy AdultsCompletedNCT00014053
• Zidovudine and Lamivudine Given Once Versus Twice DailyCompletedNCT00014014Phase 1
• HIV Maintenance Therapy With T-20 During HAART InterruptionCompletedNCT00013884Phase 2
• Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral LoadCompletedNCT00013663Phase 2
• Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV InfectionCompletedNCT00013520Phase 3
• Ritonavir and Indinavir in Children Failing Other Anti-HIV TreatmentCompletedNCT00012519Phase 1/2
• Blood Levels of Abacavir After One Dose in HIV-Infected Children and AdolescentsCompletedNCT00011479Phase 1
• Salvage Treatment, Resistance Testing, and Withdrawal of Anti-HIV Drugs for HIV Patients Failing Current Anti-HIV TreatmentWithdrawnNCT00011128Phase 3
• Effects of Storage on Lactate in Blood SamplesCompletedNCT00011050
• ALVAC-HIV vCP1452 Alone and Combined With MN rgp120CompletedNCT00011037Phase 2
• Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIVCompletedNCT00011011Phase 1/2
• Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal FatCompletedNCT00009555Phase 4
• Analysis of HIV Genetic Variation in Patients Before Beginning Highly Active Antiretroviral TherapyCompletedNCT00009256
• Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug TherapyWithdrawnNCT00008866Phase 2
• HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV DrugsCompletedNCT00007488
• Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in UgandaCompletedNCT00007423Phase 1
• Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/BCompletedNCT00007332Phase 2
• Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected PatientsCompletedNCT00006617Not applicable
• A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 YearsCompletedNCT00006509Phase 1
• Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452CompletedNCT00006495Phase 1
• Study of Tests to Evaluate Effectiveness of Anti-HIV DrugsCompletedNCT00006494
• A Comparison of Two Tests for Anti-HIV Drug ResistanceCompletedNCT00006490
• Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV InfectionCompletedNCT00006443Not applicable
• The Effects of Anti-HIV Drugs on the HIV Virus in HIV-Infected PatientsCompletedNCT00006442
• Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIVCompletedNCT00006441Not applicable
• A Test of Behavioral Intervention for Women at High Risk for HIV InfectionCompletedNCT00006440
• Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV InfectionWithdrawnNCT00006339Phase 2
• Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive ChildrenCompletedNCT00006325Phase 1
• Pharmacokinetics of Antiretroviral Agents in HIV-1 Infected Pregnant WomenCompletedNCT00006320Phase 1
• Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug CombinationCompletedNCT00006291Phase 2
• The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 MonthsCompletedNCT00006279Phase 1
• Safety and Tolerability of the Vaginal Gel PRO 2000/5CompletedNCT00006207Phase 1
• A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV InfectionCompletedNCT00006154Phase 3
• A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug TreatmentCompletedNCT00006152Phase 2
• A Study of HIV-Disease Development in AgingCompletedNCT00006144Phase 2
• Growth Hormone Treatment of Children With HIV-Associated Growth FailureCompletedNCT00006143Not applicable
• A Study of Chlorhexidine in the Prevention of HIV-1 Transmission From Mothers to Their BabiesCompletedNCT00006075Phase 2